Abstract
Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.
Highlights
“Assays and biomarkers are needed for COVID-19 trials for the purposes of patient stratification and enrollment, determining pharmacokinetics (PK), characterizing mechanism of action and ” measuring therapeutic effect
Prophylactic vaccines are being tested to produce an immune response against SARS-CoV-2
COVID-19 will likely forever change the field of drug development and bioanalysis
Summary
“Assays and biomarkers are needed for COVID-19 trials for the purposes of patient stratification and enrollment, determining pharmacokinetics (PK), characterizing mechanism of action and ” measuring therapeutic effect. Even repurposed therapies need testing with new assays specific for SARS-CoV-2. The time needed to develop these assays and their reagents is one of the major bottlenecks for SARS-CoV-2 trials.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
